Seeking Alpha

Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically...

Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically significant results of the Phase 3 of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. SLXP +11%, PGNX +18.8% premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs